Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil new alcohol warnings debuting for certain adult Tylenol products, Motrin IB.

This article was originally published in The Tan Sheet

Executive Summary

TYLENOL REVISED ALCOHOL WARNING CITING OVERDOSE RISK will be on packages beginning in late July, McNeil Consumer Products announced July 8. As part of a repackaging effort that includes redesigned front graphics and an easier-to-read format, the company has changed its alcohol warning to incorporate a reference to liver damage, as proposed by FDA in November ("The Tan Sheet" Nov. 17, 1997, p. 1). However, unlike the agency's proposed warning, McNeil's statements link the possible organ damage to taking more than the recommended dose of Tylenol.

You may also be interested in...



Women's Tylenol Marks McNeil Foray Into Menstrual Pain Category

McNeil Consumer Healthcare is backing Women's Tylenol, slated to launch in mid-October, with a dedicated TV ad campaign and public relations push.

Women's Tylenol Marks McNeil Foray Into Menstrual Pain Category

McNeil Consumer Healthcare is backing Women's Tylenol, slated to launch in mid-October, with a dedicated TV ad campaign and public relations push.

Women's Tylenol Marks McNeil Foray Into Menstrual Pain Category

McNeil Consumer Healthcare is backing Women's Tylenol, slated to launch in mid-October, with a dedicated TV ad campaign and public relations push.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel